Enlivex (ENLV) vs Propanc Biopharma (PPCB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Enlivex is the larger company by market cap ($5.1 million vs $4.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENLV | PPCB |
|---|---|---|
| Share price | $0.254 | $0.4857 |
| Market cap | $5.06M | $4.77M |
| 1-day change | -8.30% | +3.12% |
| P/E ratio (TTM) | 0.00 | — |
| EPS (TTM) | $494.00 | $-17.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.15 | $47.50 |
| 52-week low | $0.224 | $0.46 |
| Distance from 52-week high | -99.06% | -98.98% |
| Analyst consensus | none | — |
| Avg. price target upside | +31396.06% | — |
| Average volume | 992.38K | 1.79M |
| Shares outstanding | 19.91M | 9.83M |
| Employees | 34 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Enlivex
ENLV stock →Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
About Propanc Biopharma
PPCB stock →Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
ENLV vs PPCB FAQ
Which is bigger, Enlivex or Propanc Biopharma?
Enlivex (ENLV) is larger, with a market capitalization of $5.06M compared with $4.77M for Propanc Biopharma (PPCB).
Are Enlivex and Propanc Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.